Public consultation of a core health technology assessments (core HTA)
We are happy to announce that the second comprehensive Core HTA produced within the EUnetHTA Joint Action 2 Work Package 4 is available for public feedback.
The topic assessed is “Use of Intravenous immunoglobulins for Alzheimer’s disease including Mild Cognitive Impairment”
This consultation will take place between
June 18th and July 15th 2015.
Objective of public consultation
The aim of this consultation is to obtain feedback on the validity of the core HTA for its intended primary use.
A Core HTA is an extensive package of HTA information intended to serve as an information base for the production of local (e.g. national or regional) HTAs. Most information in the core HTA are presented as “result cards”, each of which contains one or few research question(s) and answer(s) to the question(s). The cards are produced and presented in a structure of nine domains (e.g. effectiveness or ethics), each providing an overview of the technology from a specific perspective.
Consultation documents
Questions and contacts
For any kind of question on the survey and on the Core HTA please contact
vicari@agenas.it
